Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab + docetaxel + cisplatin followed by surgery and pembrolizumab in locally advanced thymic epithelial tumor
KCT0004188Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in thymic malignancies (TET), sponsored by Merck & Co.. Started Sep 2019; status: active, not recruiting.
02
Drugs
03
Conditions
thymic malignancies (TET)
Beyond the preview
Go deeper on KCT0004188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004188.